TRAX (First Tracks Biotherapeutics) Total Long-Term Assets: $51.96 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $44.64
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Total Long-Term Assets?

First Tracks Biotherapeutics TRAX +1.36% 12 Total Long-Term Assets is $51.96 Mil as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. First Tracks Biotherapeutics's Total Long-Term Assets for the quarter that ended in Dec. 2024 was $51.96 Mil.

First Tracks Biotherapeutics Total Long-Term Assets Related Terms

First Tracks Biotherapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Total Long-Term Assets Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Total Long-Term Assets
45.55 51.96

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Total Long-Term Assets 45.55 51.96
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $51.96 Mil mean?
First Tracks Biotherapeutics (TRAX) has a Total Long-Term Assets of $51.96 Mil as of Dec. 2024. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Total Long-Term Assets too high?
First Tracks Biotherapeutics' current Total Long-Term Assets is $51.96 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Total Long-Term Assets compare to AVLN and IMTX?
First Tracks Biotherapeutics' Total Long-Term Assets of $51.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Total Long-Term Assets is $51.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Total Long-Term Assets of $51.96 Mil. The current Total Long-Term Assets is $51.96 Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Total Long-Term Assets is $51.96 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.64
Price